> Details

Dodel, Richard; Hampel, Harald; Depboylu, Candan; Lin, Suizhen; Gao, Feng; Schock, Sabine; Jäckel, Steffi; Wei, Xing; Buerger, Katharina; Höft, Christine; Hemmer, Bernhard; Möller, Hans‐Jürgen; Farlow, Martin; Oertel, Wolfgang H.; Sommer, Norbert; Du, Yansheng

Human antibodies against amyloid β peptide: A potential treatment for Alzheimer's disease

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Human antibodies against amyloid β peptide: A potential treatment for Alzheimer's disease
  • Contributor: Dodel, Richard; Hampel, Harald; Depboylu, Candan; Lin, Suizhen; Gao, Feng; Schock, Sabine; Jäckel, Steffi; Wei, Xing; Buerger, Katharina; Höft, Christine; Hemmer, Bernhard; Möller, Hans‐Jürgen; Farlow, Martin; Oertel, Wolfgang H.; Sommer, Norbert; Du, Yansheng
  • Published: Wiley, 2002
  • Published in: Annals of Neurology, 52 (2002) 2, Seite 253-256
  • Language: English
  • DOI: 10.1002/ana.10253
  • ISSN: 0364-5134; 1531-8249
  • Origination:
  • Footnote:
  • Description: AbstractNaturally occurring antibodies directed against β‐amyloid (Aβ) were detected in intravenous immunoglobulin preparations. After intravenous immunoglobulin treatment in patients with different neurological diseases, total Aβ and Aβ1‐42 in the cerebrospinal fluid was reduced significantly compared with baseline values. In the serum, total Aβ levels increased after intravenous immunoglobulin treatment, whereas no significant change was observed in Aβ1‐42 levels. Antibodies against Aβ were found to be increased in the serum and cerebrospinal fluid after intravenous immunoglobulin treatment. This study provides evidence that intravenous immunoglobulin or purified Aβ antibodies may modify Aβ and Aβ1‐42 levels, suggesting potential utility as a therapy for Alzheimer disease.